Research programme: anti-coronavirus monoclonal antibodies - Medarex/MBL

Drug Profile

Research programme: anti-coronavirus monoclonal antibodies - Medarex/MBL

Latest Information Update: 02 May 2007

Price : $50

At a glance

  • Originator Medarex; University of Massachusetts Medical School
  • Class Monoclonal antibodies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Coronavirus infections

Most Recent Events

  • 01 Jun 2004 Data presented at the 17th International Conference on Antiviral Research (ICAR-2004) have been added to the Viral Infections pharmacodynamics section
  • 28 Apr 2004 Medarex and MBL have shipped a fully human anti-coronvairus antibody to Sinovac Biotech Co., Ltd., in China for preclinical testing
  • 21 May 2003 Preclinical trials in Coronavirus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top